COVID-19 studies:  C19 studies: C19:  IvermectinIVM Vitamin DV.D HC QHC Q Vitamin CV.C ZincZn PVP-IPVP-I FLVFLV REGNR2 LY-CoVLY RemdesivirRMD
HCQ study #252 of 255
2/11 Late treatment study
Lora-Tamayo et al., J. Infection, doi:10.1016/j.jinf.2021.02.011 (Peer Reviewed)
Early Lopinavir/ritonavir does not reduce mortality in COVID-19 patients: results of a large multicenter study
Source   PDF   Share   Tweet
Lopinavir/ritonavir retrospective study also showing univariate results for HCQ, with significantly lower mortality.

Lora-Tamayo et al., 2/11/2021, retrospective, Spain, Europe, peer-reviewed, 10 authors.
risk of death, 50.5% lower, RR 0.50, p < 0.001, treatment 7192, control 1361, odds ratio converted to relative risk, univariate.

Effect extraction follows pre-specified rules prioritizing more serious outcomes. For an individual study the most serious outcome may have a smaller number of events and lower statistical signficance, however this provides the strongest evidence for the most serious outcomes when combining the results of many trials.
Details of all 255 studies    Meta analysis
Please send us corrections, updates, or comments.